摘要
目的采用超高效液相色谱-四极杆-飞行时间质谱联用技术(UPLC-Q/TOF-MS)对痹祺胶囊化学物质组和入血成分进行辨识研究,初步阐明其可能的药效物质基础。方法采用Acquity BEH C_(18)色谱柱(100 mm×2.1 mm,1.7μm),流动相为乙腈(A)-0.1%甲酸水溶液(B),梯度洗脱,体积流量为0.2 mL/min,柱温为30℃,进样量为5μL。采用电喷雾离子源,正、负离子模式扫描。离子源温度为110℃,锥孔电压为30 V,锥孔气体积流量为50 L/h;脱溶剂用氮气,脱气温度为350℃,体积流量为800 L/h;扫描范围为m/z 50~2000。结果在痹祺胶囊样品溶液中鉴定出280个成分,在给药大鼠血浆样品中鉴定出81个化学成分,包括59个原型成分和22个代谢产物。结论对痹祺胶囊及其入血成分进行了较全面地研究,初步阐明痹祺胶囊的药效物质基础,为痹祺胶囊的后续研究提供了理论基础。。
Objective To identify the chemical substance and blood components of Biqi Capsules(痹祺胶囊),and preliminarily clarify its possible medicinal substances basis by ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry(UPLC-Q/TOF-MS).Methods The separation was performed on Acquity BEH C18 chromatographic column(100 mm×2.1mm,1.7μm)with mobile phase of acetonitrile(A)-0.1%formic acid aqueous solution(B)for gradient elution at volume flow rate of 0.2 mL/min under column temperature of 30℃.The injection volume was 5μL.The electrospray ion source was used for scanning in positive and negative ion modes.Ion source temperature was 110℃,cone voltage was 30 V,cone gas volume flow was 50 L/h,nitrogen degassing temperature was 350℃,degassing volume flow was 800 L/h,scanning range m/z 50—2000.Results A total of 280 components were identified in Biqi Capsule sample solution,and 81 chemical components were identified in plasma samples,including 59 prototype components and 22 metabolites.Conclusion This experiment conducted a more comprehensive study of Biqi Capsules and their blood components,and initially clarified the material basis of the efficacy of Biqi Capsules,and provided a theoretical basis for the follow-up research of Biqi Capsules.
作者
刘建庭
仉瑜
卜睿臻
赵鸿鹏
赵宇
张洪兵
许浚
张铁军
王磊
刘昌孝
LIU Jian-ting;ZHANG Yu;BU Rui-zhen;ZHAO Hong-peng;ZHAO Yu;ZHANG Hong-bing;XU Jun;ZHANG Tie-jun;WANG Lei;LIU Chang-xiao(State Key Laboratory of Drug Delivery Technology and Pharmacokinetics,Tianjin Institute of Pharmaceutical Research,Tianjin 300462,China;Tianjin Key Laboratory of Quality Marker of Traditional Chinese Medicine,Tianjin Institute of Pharmaceutical Research,Tianjin 300193,China;Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China;Tianjin Darentang Jingwanhong Pharmaceutical Co.,Ltd.,Tianjin 300112,China)
出处
《中草药》
CAS
CSCD
北大核心
2021年第18期5496-5513,共18页
Chinese Traditional and Herbal Drugs
基金
国家自然科学基金重点项目(81830111)
天津市科技计划项目中央引导地方科技发展专项(20ZYCGSN00200)
国家中医药管理局国际合作司中医药国际合作专项(0610-2040NF020928)。
